{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:07:23Z","timestamp":1789142843466,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97517-y","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:12:38Z","timestamp":1745759558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis \u2013 a real-world experience"],"prefix":"10.1038","volume":"15","author":[{"given":"Chih-Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou-Tsern","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chung","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"97517_CR1","unstructured":"World Health Organization, G. Switzerland. Global Tuberculosis Report 2023. (2023)."},{"key":"97517_CR2","unstructured":"World Health Organization. WHO operational handbook on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. (2022)."},{"issue":"7","key":"97517_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid, P. et al. Executive summary: official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of Drug-Susceptible tuberculosis. Clin. Infect. Dis. 63 (7), 853\u2013867. https:\/\/doi.org\/10.1093\/cid\/ciw376 (2016).","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"97517_CR4","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid, P. et al. Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of Drug-Susceptible tuberculosis. Clin. Infect. Dis. 63 (7), e147\u2013e95. https:\/\/doi.org\/10.1093\/cid\/ciw376 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"97517_CR5","unstructured":"Centers for Disease Control MoHaW. R.O.C.(Taiwan). Taiwan Guidelines for TB Diangosis and Treatment 5th edn. (Center for Disease Control, Executive Yuan, Taiwan (R.O.C.) 2022)."},{"issue":"2","key":"97517_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1378\/chest.14-0918","volume":"147","author":"JY Wang","year":"2015","unstructured":"Wang, J. Y. et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest 147 (2), 520\u2013528. https:\/\/doi.org\/10.1378\/chest.14-0918 (2015).","journal-title":"Chest"},{"key":"97517_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav. Res. Methods. 41, 1149\u20131160 (2009). https:\/\/shorturl.at\/axiw6","journal-title":"Behav. Res. Methods"},{"key":"97517_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2214\/ajr.143.3.509","volume":"143","author":"WJ Tuddenham","year":"1984","unstructured":"Tuddenham, W. J. Glossary of terms for thoracic radiology: recommendations of the nomenclature committee of the Fleischner society. Am. J. Roentgenol. 143, 509\u2013517 (1984).","journal-title":"Am. J. Roentgenol."},{"issue":"1","key":"97517_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. (Engl Ed). 112 (1), 90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009 (2021).","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"3","key":"97517_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.pulmoe.2020.09.006","volume":"28","author":"S Natarajan","year":"2022","unstructured":"Natarajan, S. et al. Treatment interruption patterns and adverse events among patients on bedaquiline containing regimen under programmatic conditions in India. Pulmonology 28 (3), 203\u2013209. https:\/\/doi.org\/10.1016\/j.pulmoe.2020.09.006 (2022).","journal-title":"Pulmonology"},{"key":"97517_CR11","unstructured":"Corp, B. M. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp. https:\/\/www.ibm.com\/products\/spss-statistics"},{"issue":"4","key":"97517_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1183\/13993003.01356-2016","volume":"48","author":"G Sotgiu","year":"2016","unstructured":"Sotgiu, G. et al. The ERS-endorsed official ATS\/CDC\/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur. Respir. J. 48 (4), 963\u2013971. https:\/\/doi.org\/10.1183\/13993003.01356-2016 (2016).","journal-title":"Eur. Respir J."},{"issue":"7","key":"97517_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1164\/rccm.201607-1419ED","volume":"194","author":"ML Metersky","year":"2016","unstructured":"Metersky, M. L. & Schluger, N. W. New guidelines for the treatment of Drug-Susceptible tuberculosis from the American thoracic society, centers for disease control and prevention, and the infectious diseases society of America. Now comes the hard part. Am. J. Respir. Crit. Care Med. 194 (7), 791\u2013793. https:\/\/doi.org\/10.1164\/rccm.201607-1419ED (2016).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"2","key":"97517_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4046\/trd.2015.78.2.47","volume":"78","author":"JY Lee","year":"2015","unstructured":"Lee, J. Y. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc. Respir. Dis. (Seoul). 78 (2), 47\u201355. https:\/\/doi.org\/10.4046\/trd.2015.78.2.47 (2015).","journal-title":"Tuberc Respir Dis. (Seoul)"},{"issue":"6","key":"97517_CR15","doi-asserted-by":"publisher","first-page":"e13949","DOI":"10.1111\/tid.13949","volume":"24","author":"MV Radisic","year":"2022","unstructured":"Radisic, M. V. et al. Tuberculosis treatment without Rifampin in kidney\/kidney-pancreas transplantation: A case series report. Transpl. Infect. Dis. 24 (6), e13949. https:\/\/doi.org\/10.1111\/tid.13949 (2022).","journal-title":"Transpl. Infect. Dis."},{"issue":"4","key":"97517_CR16","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1378\/chest.128.4.2218","volume":"128","author":"DK Kim","year":"2005","unstructured":"Kim, D. K. et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest 128 (4), 2218\u20132222. https:\/\/doi.org\/10.1378\/chest.128.4.2218 (2005).","journal-title":"Chest"},{"key":"97517_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/1471-2407-14-770","volume":"14","author":"T Hirashima","year":"2014","unstructured":"Hirashima, T. et al. Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium Kansasii infection: a retrospective study. BMC Cancer. 14, 770. https:\/\/doi.org\/10.1186\/1471-2407-14-770 (2014).","journal-title":"BMC Cancer"},{"issue":"1","key":"97517_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1186\/s12885-018-4889-1","volume":"18","author":"T Hirashima","year":"2018","unstructured":"Hirashima, T. et al. Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in cancer patients with active Mycobacterium tuberculosis: a retrospective study. BMC Cancer. 18 (1), 975. https:\/\/doi.org\/10.1186\/s12885-018-4889-1 (2018).","journal-title":"BMC Cancer"},{"key":"97517_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ijid.2021.09.072","volume":"113","author":"CS Lee","year":"2021","unstructured":"Lee, C. S., Shu, C. C., Chen, Y. C., Liao, K. M. & Ho, C. H. Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors. Int. J. Infect. Dis. 113, 200\u2013206. https:\/\/doi.org\/10.1016\/j.ijid.2021.09.072 (2021).","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"97517_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/hep.510310129","volume":"31","author":"WM Wong","year":"2000","unstructured":"Wong, W. M. et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31 (1), 201\u2013206. https:\/\/doi.org\/10.1002\/hep.510310129 (2000).","journal-title":"Hepatology"},{"issue":"5","key":"97517_CR21","first-page":"616","volume":"14","author":"JY Chien","year":"2010","unstructured":"Chien, J. Y. et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis. 14 (5), 616\u2013621 (2010).","journal-title":"Int. J. Tuberc Lung Dis."},{"issue":"12","key":"97517_CR22","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.5588\/ijtld.18.0195","volume":"22","author":"AP Chua","year":"2018","unstructured":"Chua, A. P., Lim, L. K., Gan, S. H., Chee, C. B. & Wang, Y. T. The role of chronic viral hepatitis on tuberculosis treatment interruption. Int. J. Tuberc. Lung Dis. 22 (12), 1486\u20131494. https:\/\/doi.org\/10.5588\/ijtld.18.0195 (2018).","journal-title":"Int. J. Tuberc Lung Dis."},{"issue":"18","key":"97517_CR23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman, S. E. et al. Four-Month rifapentine regimens with or without Moxifloxacin for tuberculosis. N. Engl. J. Med. 384 (18), 1705\u20131718. https:\/\/doi.org\/10.1056\/NEJMoa2033400 (2021).","journal-title":"N Engl. J. Med."},{"issue":"10","key":"97517_CR24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa2212537","volume":"388","author":"NI Paton","year":"2023","unstructured":"Paton, N. I. et al. Treatment strategy for Rifampin-Susceptible tuberculosis. N. Engl. J. Med. 388 (10), 873\u2013887. https:\/\/doi.org\/10.1056\/NEJMoa2212537 (2023).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97517-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:12:40Z","timestamp":1745759560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97517-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97517"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97517-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14709"}}